Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Anakinra Stories

2012-06-07 11:58:43

Results of a separate study demonstrate that early and sustained remission are associated with decrease mortality According to a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, patients with rheumatoid arthritis (RA) who are prescribed biologic treatments have a significantly lower mortality risk (adjusted hazard ratio [HR]: 0.61) than those just treated with traditional disease modifying anti-rheumatic drugs (DMARDs). The study also...

2012-06-07 11:54:21

For every additional 6 months of treatment CV risk reduces further Results from a retrospective analysis of contemporary data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, predict, based on estimates from a multivariate regression model, that the cumulative use of anti-tumor necrosis factor drugs (anti-TNFs) for one, two, or three years is associated with reduced risk of cardiovascular events by 24%, 42% and 56% in patients with rheumatoid...

2012-06-06 12:30:57

Safety results were similar between groups Data presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that tocilizumab monotherapy is more effective than adalimumab monotherapy in the treatment of rheumatoid arthritis (RA) based on change from baseline in DAS28 (-3.3 vs. -1.8, p<0.0001) at week 24. The ADACTA trial, conducted in 325 patients with RA showed that tocilizumab was more effective than adalimumab for DAS28 remission (39.9%...

2012-06-06 06:26:26

BERLIN and BRUSSELS, June 6, 2012 /PRNewswire/ -- Results from the RAPID(TM)-PsA study presented this week at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Germany showed that certolizumab pegol compared to placebo improved the signs and symptoms of arthritis in adult patients with active psoriatic arthritis (PsA). "Certolizumab pegol has been shown to be clinically effective in moderate to severe rheumatoid arthritis. The RAPID(TM)-PsA study is...

2012-06-06 02:25:18

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the Phase 3 ABILITY-2 investigational study of HUMIRA® (adalimumab) in patients with active peripheral spondyloarthritis (PSpA) who have not been diagnosed with psoriatic arthritis (PsA) or ankylosing spondylitis (AS). At week 12, nearly twice as many HUMIRA patients compared to those receiving placebo achieved the primary endpoint, defined as at least a 40 percent improvement in the peripheral SpA...

2012-06-05 18:22:56

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from two long-term, open-label studies, which evaluated the results of HUMIRA® (adalimumab) treatment for up to 10 years in patients with long-standing, moderate-to-severe rheumatoid arthritis (RA). These 10-year HUMIRA studies, DE019 and DE020, are among the longest, open-label trials in RA. Results presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany, include...

2012-06-05 18:22:52

BERLIN, June 6, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced results from the open-label extension of the Phase 3 ABILITY-1 investigational study of HUMIRA® (adalimumab), which assessed the improvement in signs and symptoms of disease for patients with active axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Results were presented at the European League Against Rheumatism (EULAR) 2012 Congress in Berlin, Germany. ABILITY-1 is the first large,...

2012-06-05 14:21:04

BERLIN, June 5, 2012 /PRNewswire/ -- Phase 3 study findings presented today showed that patients with active moderate to severe rheumatoid arthritis (RA) who received an investigational intravenous (I.V.) formulation of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI(®) (golimumab) [hereafter referred to as SIMPONI I.V.] demonstrated significant improvements in signs and symptoms and disease activity. Investigators reported nearly 60 percent of patients receiving SIMPONI I.V....

2012-06-01 02:23:47

BRUSSELS, June 1, 2012 /PRNewswire/ -- UCB, a leading biopharmaceutical company, is sponsoring several data presentations for its immunology portfolio at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin, Germany, June 6-9, 2012. "We are pleased to show our continued commitment to improving the lives of those living with autoimmune diseases," said Professor Dr. Iris Loew-Friedrich, Chief Medical Officer and Executive Vice President, UCB. "The...

2012-05-28 18:20:14

ABBOTT PARK, Ill., May 29, 2012 /PRNewswire/ -- Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA® (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012. The presentations include two of the longest open-label extension studies in rheumatoid arthritis (RA), featuring long-term data for disease activity and radiographic inhibition. Data will also be presented on...